FDA panel greenlights five peptides for compounding pharmacies

Peptides are short chains of amino acids, the building blocks of proteins. They have been used for years by biohackers and fitness enthusiasts for purposes such as muscle recovery, wound healing, and cognitive performance. Scientific evidence for most applications remains limited. The panel members weighed the available evidence for each compound individually.

Which peptides were approved?

After two days of deliberation, the advisory committee voted to recommend allowing compounding pharmacies to manufacture BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax. The peptide emideltide was narrowly rejected. The committee’s votes are not binding; the final decision rests with the FDA. The agency generally follows such recommendations, though exceptions have occurred.

The votes align with the political agenda of health secretary Robert F. Kennedy Jr., who has pushed to make peptides more accessible to Americans. Critics point to the lack of clinical evidence and the risks of uncontrolled production by compounding pharmacies. Proponents argue that legalisation would actually enable quality controls that are currently absent.

What does this mean for longevity users?

Peptides such as BPC-157 and epitalon are popular in longevity circles but are supported by very few human clinical trials. Availability through regulated pharmacies brings quality oversight, but does not make them proven treatments. Users should distinguish between availability and evidence. For users outside the United States, nothing changes for now: other jurisdictions maintain different rules for compounded medicines.

Read the original article